Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex

Neuroscience Letters

Volumn 497, Issue 2, 2011, Pages 99-103

  Agostinho, Fabiano R ^a   Réus, Gislaine Z ^a   Stringari, Roberto B ^a   Ribeiro, Karine F ^a   Pfaffenseller, Bianca ^b   Stertz, Laura ^b   Panizzutti, Bruna S ^b   Kapczinski, Flávio ^b   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Brain derived neurotrophic factor; Fluoxetine; Mood disorder; Nerve growth factor; Neurotrophin 3; Olanzapine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; OLANZAPINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; HIPPOCAMPUS; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOXETINE; MALE; NEUROTROPHIN 3; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; UP-REGULATION;

EID: 79956301622     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.04.039     Document Type: Article

References (67)

1. Agostinho F.R., Scaini G., Ferreira G.K., Jeremias I.C., Réus G.Z., Rezin G.T., Castro A.A., Zugno A.I., Quevedo J., Streck E.L. Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res. Bull. 2009, 80:337-340.
2. Agostinho F.R., Réus G.Z., Stringari R.B., Ribeiro K.F., Ferraro A.K., Benedet J., Rochi N., Scaini G., Streck E.L., Quevedo J. Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain. Neurosci. Lett. 2011, 487:278-281.
3. Aloe L., Iannitelli A., Bersani G., Alleva E., Angelucci F., Maselli P., Manni L. Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Neuropsychobiology 1997, 36:65-68.
4. Altar C., DiStefano P.S. Neurotrophin trafficking by anterograde transport. Trends Neurosci. 1998, 21:433-437.
5. Altieri M., Marini F., Arban R., Vitulli G., Jansson B.O. Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment. Brain Res. 2004, 1000:148-155.
6. Angelucci F., Aloe L., Jimenez-Vasquez P.A., Mathe A.A. Mapping the differences in the brain concentration of BDNF and NGF in an animal model of depression. NeuroReport 2000, 11:69-1373.
7. Angelucci F., Aloe L., Iannitelli A., Grubera S.H.M., Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur. Neuropsychopharmacol. 2005, 15:311-317.
8. Arango V., Underwood M.D., Gubbi A.V., Mann J.J. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res. 1995, 688:121-133.
9. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 2003, 71:127-131.
10. Balu D.T., Hoshaw B.A., Malberg J.E., Rosenzweig-Lipson S., Schechter L.E., Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 2008, 1211:37-43.
11. Baker R.M., Brown E., Akiskal H.S., Calabrese J.R., Ketter T.A., Schuh L.M., Trzepacz P.T., Watkin J.G., Tohen M. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br. J. Psychiatry 2004, 185:472-478.
12. Barbosa I.G., Huguet R.B., Neves F.S., Reis H.J., Bauer M.E., Janka Z., Palotás A., Teixeira A.L. Impaired nerve growth factor homeostasis in patients with bipolar disorder. World J. Biol. Psychiatry 2011, 12:228-232.
13. Bersani G., Iannitelli A., Maselli P., Pancheri P., Aloe L., Angelucci F., Alleva E. Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophr. Res. 1999, 37:201-203.
14. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am. J. Psychiatry 2000, 157:115-118.
15. Brown R.W., Perna K.M., Maplea A.M., Wilson T.D., Miller B.E. Adulthood olanzapine treatment fails to alleviate decreases of ChAT and BDNF RNA expression in rats quinpirole-primed as neonates. Brain Res. 2008, 1200:66-77.
16. Coppell A.L., Pei Q., Zetterstrom T.S.C. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003, 44:903-910.
17. Cunha A.B., Frey B.N., Andreazza A.C., Godoi J.D., Rosa A.R., Gonçalves C.A., Santin A., Kapczinski F. Serum brain-derived neurotrophic is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 2006, 398:215-219.
18. Czubak A., Nowakowska E., Kus K., Burda K., Metelska J., Baer-Dubowska W., Cichocki M. Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol. Rep. 2009, 61:1017-1023.
19. Dias B.G., Banerjee S.B., Duman R.S., Vaidya V.A. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003, 45:553-563.
20. Drevets W.C., Price J.L., Simpson J.R., Todd R.D.R.D., Reich T., Vannier M., Raichle M.E. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997, 386:824-827.
21. Du J., Wang Y., Hunter R., Wei Y., Blumenthal R., Falke C., Khairova R., Zhou R., Yuan P., Machado-Vieira R., McEwen B.S., Manji H.K. Dynamic regulation of mitochondrial function by glucocorticoids. PNAS 2009, 106:3543-3548.
22. Duman R.S., Monteggia L.M. A neurotrophic model for stress related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
23. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001, 52:79-86.
24. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., Manji H.K., Chen G. The role of the extracellular signal-regulated kinase pathway in mood modulation. J. Neurosci. 2003, 23:7311-7316.
25. Fernandes B.S., Gama C.S., Walz J.C., Ceresér K.M., Fries G.R., Colpo G., Aguiar B., Pfaffenseller B., Kauer-Sant'Anna M., Kapczinski F. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J. Psychiatr. Res. 2010, 44:561-565.
26. Fountoulakis K.N., Vieta E., Sanchez-Moreno J., Kaprinis S.G., Goikolea J.M., Kaprinis G.S. Treatment guidelines for bipolar disorder: a critical review. J. Affect. Disord. 2005, 86:1-10.
27. Gazalle F.K., Andreazza A.C., Hallal P.C., Kauer-Sant'Anna M., Ceresér K.M., Soares J.C., Santin A., Kapczinski F. Bipolar depression: the importance of being on remission. Rev. Bras. Psiquiatr. 2006, 28:93-96.
28. Goldberg J., Barres B.A. The relationship between neuronal survival and regeneration. Ann. Rev. Neurosci. 2000, 23:579-612.
29. González-Pinto A., Mosquera F., Palomino A., Alberich S., Gutiérrez A., Haidar K., Vega P., Barbeito S., Ortiz A., Matute C. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int. Clin. Psychopharmacol. 2010, 25:241-245.
30. Hellweg R., Ziegenhorn A., Heuser I., Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 2008, 41:66-71.
31. Hori H., Yoshimura R., Yamada Y., Ikenouchi A., Mitoma M., Ida Y., Nakamura J. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int. Clin. Psychopharmacol. 2007, 22:21-27.
32. Huang E.J., Reichardt L.F. Neurotrophins: role in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
33. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry. 2002, 59:530-537.
34. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002, 15:143-148.
35. Lee J.G., Cho H.Y., Park S.W., Seo M.K., Kim Y.H. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Progr. NeuroPsychopharmacol. Biol. Psychiatry 2010, 34:1001-1006.
36. Lessmann V., Gottmann K., Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 2003, 69:341-374.
37. Li Y.F., Liu Y.Q., Huang W.C., Luo Z.P. Cytoprotective effect is one of common action pathways for antidepressants. Acta Pharmacol. Sin. 2003, 24:996-1000.
38. Lindsay R.M., Wiegand S.J., Altar C.A., DiStefano P.S. Neurotrophic factors: from molecule to man. Trends Neurosci. 1994, 17:182-190.
39. Lowry O.H., Rosebough N.G., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
40. Matthews J.D., Bottonari K.A., Polania L.M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J. Clin. Psychiatry 2002, 63:1164-1170.
41. Miro X., Perez-Torres S., Artigas F., Puigdomenech P., Palacios J.M., Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 2002, 43:1148-1157.
42. Molteni R., Calabrese F., Bedogni F., Tongiorgi E., Fumagalli F., Racagni G., Riva M.A. Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int. J. Neuropsychopharmacol. 2006, 9:307-317.
43. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 1996, 16:2365-2372.
44. Nishimura T., Ishima T., Iyo M., Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008, 3:2558.
45. Otsuki K., Uchida S., Watanuki T., Wakabayashi Y., Fujimoto M., Matsubara T., Funato H., Watanabe Y. Altered expression of neurotrophic factors in patients with major depression. J. Psychiatr. Res. 2008, 42:1145-1153.
46. Parikh V., Terry A.V., Khan M.M., Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology 2004, 172:365-374.
47. Perlis R.H., Ostacher M.J., Goldberg J.F., Miklowitz D.J., Friedman E., Calabrese J., Thase M.E., Sachs G.S. Transition to Mania During Treatment of Bipolar Depression. Neuropsychopharmacology 2010, 35:2545-2552.
48. Pillai A., Terry A.V., Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 2006, 82:95-106.
49. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., Katsafouros K., Lykouras L. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J. Biol. Psychiatry 2008, 10:1-5.
50. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., Katsafouros K., Lykouras L. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J. Biol. Psychiatry 2010, 11:251-255.
51. Schinder A.F., Poo M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci. 2000, 23:639-645.
52. Schulte-Herbrüggen O., Fuchs E., Abumaria N., Ziegler A., Danker-Hopfe H., Hiemke C., Hellweg R. Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J. Neurosci. Res. 2009, 87:2551-2560.
53. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Acobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 2001, 158:131-134.
54. Shi C.G., Wang L.M., Wu Y., Wang P., Gan Z.J., Lin K., Jiang L.X., Xu Z.Q., Fan M. Intranasal administration of nerve growth factor produces antidepressant-like effects in animals. Neurochem. Res. 2010, 35:1302-1314.
55. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
56. Smith M.A. Hippocampal vulnerability to stress and aging: possible role of neurotrophic factors. Behav. Brain Res. 1996, 78:25-36.
57. Smith M.A., Makino S., Kvetnansky R., Post R.M. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNA in the hippocampus. J. Neurosci. 1995, 15:1768-1777.
58. Tamayo J.M., Sutton K.V., Mattei M.A., Diaz B., Jamal H.H., Vieta E., Tohen M. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J. Clin. Psychopharmacol. 2009, 29:358-361.
59. Tohen M., Baker R.W., Altshuler L.L., Zarate C.A., Suppes T., Ketter T.A., Milton D.R., Risser R., Gilmore J.A., Breier A., Tollefson G.A. Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry 2002, 159:1011-1017.
60. Tohen M., Greil W., Calabrese J.R., Sachs G.S., Yatham L.N., Oerlinghausen B.M., Koukopoulos A., Cassano G.B., Grunze H., Licht R.W., Dell'Osso L., Evans A.R., Risser R., Baker R.W., Crane H., Dossenbach M.R., Bowden C.K. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry 2005, 162:1281-1290.
61. Tohen M., Jacobs T.G., Grundy S.L., McElroy S.L., Banov M.C., Janicak P.G., Sanger T.M., Risser R., Zhang F., Toma V., Francis B.J., Tollefson G.D., Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2000, 57:841-849.
62. Tohen M., Ketter T.A., Zarate C.A., Suppes T., Frye M., Altshuler L., Zajecka J., Schuh L.M., Risser R.C., Brown E., Baker R.W. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry 2003, 160:1263-1271.
63. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N.R., Daniel D.G., Petty F., Centorrino F., Wang R., Grundy S.L., Greaney M.G., Jacobs T.G., David S.R., Toma V. Olanzapine versus placebo in the treatment of acute mania. Am. J. Psychiatry 1999, 156:702-709.
64. Tollefson G.D., Sanger T.M., Lu M.K., Thieme M.E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psychiatry. 1998, 55:250-258.
65. Vieta E., Sanchez-Moreno J. Acute and long-term treatment of mania. Dialogues Clin. Neurosci. 2008, 10:165-179.
66. Vieta E. Olanzapine in bipolar disorder. Exp. Opin. Pharmacother. 2004, 5:1613-1619.
67. Yoshimura R., Ueda N., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J. Biol. Psychiatry 2010, 11:256-261.